Effects of topical Janus Kinase inhibition on ocular surface inflammation and immunity

Cornea

Volumn 33, Issue 2, 2014, Pages 177-183

  Stevenson, William ^a   Sadrai, Zahra ^a   Hua, Jing ^a   Kodati, Shilpa ^a   Huang, Jing Feng ^b   Chauhan, Sunil K ^a   Dana, Reza ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b PFIZER INC   (United States)

Author keywords

Corneal thermocautery; Dry eye disease; Janus kinase; Ocular surface inflammation; Tofacitinib (CP 690,550)

Indexed keywords

CD11B ANTIGEN; CD45 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; JANUS KINASE; TOFACITINIB; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CAUTERIZATION; CONJUNCTIVA; CONTROLLED STUDY; CORNEA SURGERY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFECT; DRY EYE; ENZYME INHIBITION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNITY; IMMUNOHISTOCHEMISTRY; KERATITIS; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHYSICAL STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADAPTIVE IMMUNITY; ADMINISTRATION, TOPICAL; ANIMALS; ANTIGENS, CD11B; ANTIGENS, CD45; CELL MOVEMENT; CYTOKINES; DISEASE MODELS, ANIMAL; DRY EYE SYNDROMES; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; JANUS KINASE 3; KERATITIS; LEUKOCYTES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OPHTHALMIC SOLUTIONS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CHEMOKINE;

EID: 84892960749     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0000000000000019     Document Type: Article

References (33)

1. Clements JL, Dana R. Inflammatory corneal neovascularization: Etiopathogenesis. Semin Ophthalmol. 2011;26:235-245.
2. Sadrai Z, Hajrasouliha AR, Chauhan S, et al. Effect of topical azithromycin on corneal innate immune responses. Invest Ophthalmol Vis Sci. 2011;52:2525-2531.
3. Stevenson W, Chauhan SK, Dana R. Dry eye disease: An immunemediated ocular surface disorder. Arch Ophthalmol. 2012;130:90-100.
4. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: Benefits and risks. Drug Saf. 2002;25:33-55.
5. Pesu M, Laurence A, Kishore N, et al. Therapeutic targeting of Janus kinases. Immunol Rev. 2008;223:132-142.
6. Kisseleva T, Bhattacharya S, Braunstein J, et al. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002; 285:1-24.
7. Vijayakrishnan L, Venkataramanan R, Gulati P. Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends Pharmacol Sci. 2011;32:25-34.
8. Dekaris I, Zhu SN, Dana MR. TNF-Alpha regulates corneal Langerhans cell migration. J Immunol. 1999;162:4235-4239.
9. Barabino S, Shen L, Chen L, et al. The controlled-environment chamber: A new mouse model of dry eye. Invest Ophthalmol Vis Sci. 2005;46: 2766-2771.
10. Goyal S, Chauhan SK, Zhang Q, et al. Amelioration of murine dry eye disease by topical antagonist to chemokine receptor 2. Arch Ophthalmol. 2009;127:882-887.
11. Sadrai Z, Stevenson W, Okanobo A, et al. PDE4 inhibition suppresses IL-17-Associated immunity in dry eye disease. Invest Ophthalmol Vis Sci. 2012;53:3584-3591.
12. Lemp MA. Report of the National Eye Institute/Industry Workshop on clinical trials in dry eyes. CLAO J. 1995;21:221-232.
13. Cannon JG. Inflammatory cytokines in nonpathological states. News Physiol Sci. 2000;15:298-303.
14. Aaronson DS, Horvath CM. A road map for those who don't know JAKSTAT. Science. 2002;296:1653-1655.
15. Rodig SJ, Meraz MA, White JM, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokineinduced biologic responses. Cell. 1998;93:373-383.
16. Noguchi M, Yi H, Rosenblatt HM, et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 1993;73:147-157.
17. Macchi P, Villa A, Giliani S, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature. 1995;377:65-68.
18. Russell SM, Tayebi N, Nakajima H, et al. Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development. Science. 1995;270:797.
19. Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond). 2010;7:41.
20. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60:1895-1905.
21. Busque S, Leventhal J, Brennan DC, et al. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: A pilot study in de novo kidney allograft recipients. Am J Transplant. 2009;9: 1936-1945.
22. Boy MG, Wang C, Wilkinson BE, et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol. 2009;129:2299-2302.
23. Hamrah P, Dana MR. Corneal antigen-presenting cells. Chem Immunol Allergy. 2007;92:58-70.
24. Hamrah P, Liu Y, Zhang Q, et al. Alterations in corneal stromal dendritic cell phenotype and distribution in inflammation. Arch Ophthalmol. 2003; 121:1132-1140.
25. Dana MR, Dai R, Zhu S, et al. Interleukin-1 receptor antagonist suppresses Langerhans cell activity and promotes ocular immune privilege. Invest Ophthalmol Vis Sci. 1998;39:70-77.
26. Dana R. Comparison of topical interleukin-1 vs tumor necrosis factor-Alpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2007;105:330-343.
27. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186: 4234-4243.
28. Chen Y, Chauhan SK, Saban DR, et al. Interferon-g-secreting NK cells promote induction of dry eye disease. J Leukoc Biol. 2011;89:965-972.
29. De Paiva CS, Chotikavanich S, Pangelinan SB, et al. IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol. 2009;2:243-253.
30. Chauhan SK, El Annan J, Ecoiffier T, et al. Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J Immunol. 2009;182:1247-1252.
31. Sewgobind VD, Quaedackers ME, van der Laan LJ, et al. The Jak inhibitor CP-690,550 preserves the function of CD4CD25FoxP3 regulatory T cells and inhibits effector T cells. Am J Transplant. 2010;10:1785-1795.
32. Liew SH, Nichols KK, Klamerus KJ, et al. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: Results from a phase 1/2 trial. Ophthalmology. 2012;119:1328-1335.
33. Huang JF, Yafawi R, Zhang M, et al. Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease. Ophthalmology. 2012;119:e43-e50.